Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies

March 8, 2017 Financial Reports

Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies

Total investment can reach EUR 13 million upon exercise of share subscription warrants

Zutphen, The Netherlands – 08 March 2017

read more

ESPERITE N.V.: Update on Financing

December 31, 2016 Group News

Esperite N.V. (Euronext: ESP, “Esperite” or “the Group”) announced during the year 2016 that it prepares a significant external funding to which the main shareholder will contribute along with potential other investors. The Group needs financial contribution to consolidate the existing business and accelerate its development for the benefit of its present and future shareholders.

Zutphen, The Netherlands – 31 December 2016

read more

Esperite N.V. (ESP) expands extracellular vesicles (exosomes) products portfolio to include inflammatory bowel disease.

October 20, 2016 Group News

The Cell Factory develops therapy for Crohn’s disease.

Esperite’s business unit The Cell Factory, in collaboration with Women’s and Children’s Health Department of the University of Padua and the Padua University Hospital have started a translational project on extracellular vesicles (including exosomes) first in man use in treatment of Crohn’s disease perianal fistulas. Inflammatory bowel disease (IBD) affects approximately 0.5% of the western countries population and this number is rapidly increasing. There are over 0.5 million people in the US and over 1 million in Europe with Crohn’s disease, with over 10 new cases per 100.000 people every year. The annual cost of therapy exceeds 5 billion USD in the US only (CDC). Up to 50% of Crohn’s disease patients are affected with difficult to treat perianal fistulas, and 75% require surgery (CDC).

Zutphen, The Netherlands – 20 October 2016

Esperite (ESP) leads international consortium for clinical translation of extracellular vesicles use in various therapies

September 30, 2016 Group News

Extracellular vesicles (EVs) disruptive technology targets unmet needs in neuroinflammatory diseases at lower costs than allogenic stem cell therapies.

Esperite’s business unit The Cell Factory develops EVs-based therapeutics in treatment of drug-resistant epilepsy in children jointly with Bambino Gesù Children’s Hospital, Mario Negri Institute for Pharmacological Research and the Women’s and Children’s Health Department of the University of Padua.

Zutphen, The Netherlands – 30 September 2016

read more